作者: Takefumi Inada , Atsuko Shirane , Nobuyuki Hamano , Makiko Yamada , Tomoko Kambara
DOI: 10.1080/08923970500240883
关键词: Intensive care 、 Interleukin 、 Spleen 、 Dexmedetomidine 、 Immunology 、 Antigen-presenting cell 、 Agonist 、 Medicine 、 Helper T lymphocyte 、 Pharmacology 、 Cytotoxic T cell 、 Toxicology 、 Immunology and Allergy 、 General Medicine
摘要: Dexmedetomidine, a selective α2 adrenergic receptor agonist, is drug often used for sedation. Despite the high prevalence of sedating patients with tumors in intensive care settings, little known about effect sedative drugs on tumor growth. We studied dexmedetomidine antitumor immunity mice. Subhypnotic doses decreased interleukin (IL)-12 production from thioglycollate-induced macrophages. The treatment also ratio helper T lymphocytes subsets, Th1 to Th2 (Th1/Th2), spleen. Following subcutaneous inoculation EL4 T-cell lymphoma cells, further splenic Th1/Th2 and activity EL4-specific cytotoxic (CTLs). Finally, accelerated growth These data show that mice subhypnotic downregulates immunity, possibly through IL-12 antigen presenting resultin...